Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Differences between colon and rectal cancer in complications, short-term survival and recurrences.

van der Sijp MP, Bastiaannet E, Mesker WE, van der Geest LG, Breugom AJ, Steup WH, Marinelli AW, Tseng LN, Tollenaar RA, van de Velde CJ, Dekker JW.

Int J Colorectal Dis. 2016 Oct;31(10):1683-91. doi: 10.1007/s00384-016-2633-3.

2.

Epigenetic therapy in gastrointestinal cancer: the right combination.

Abdelfatah E, Kerner Z, Nanda N, Ahuja N.

Therap Adv Gastroenterol. 2016 Jul;9(4):560-79. doi: 10.1177/1756283X16644247. Review.

3.

Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer.

Cha Y, Kim KJ, Han SW, Rhee YY, Bae JM, Wen X, Cho NY, Lee DW, Lee KH, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Kang GH, Kim TY.

Br J Cancer. 2016 Jul 12;115(2):164-71. doi: 10.1038/bjc.2016.176.

PMID:
27310704
4.

Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy.

Murcia O, Juárez M, Hernández-Illán E, Egoavil C, Giner-Calabuig M, Rodríguez-Soler M, Jover R.

World J Gastroenterol. 2016 Apr 7;22(13):3516-30. doi: 10.3748/wjg.v22.i13.3516. Review.

5.

Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer.

Carethers JM, Jung BH.

Gastroenterology. 2015 Oct;149(5):1177-1190.e3. doi: 10.1053/j.gastro.2015.06.047. Review.

6.

Promoter hypermethylation of tumour suppressor genes as potential biomarkers in colorectal cancer.

Ng JM, Yu J.

Int J Mol Sci. 2015 Jan 22;16(2):2472-96. doi: 10.3390/ijms16022472. Review.

7.

γ-Glutamyl hydrolase modulation significantly influences global and gene-specific DNA methylation and gene expression in human colon and breast cancer cells.

Kim SE, Hinoue T, Kim MS, Sohn KJ, Cho RC, Cole PD, Weisenberger DJ, Laird PW, Kim YI.

Genes Nutr. 2015 Jan;10(1):444. doi: 10.1007/s12263-014-0444-0.

8.

The molecular pathogenesis of colorectal cancer and its potential application to colorectal cancer screening.

Grady WM, Markowitz SD.

Dig Dis Sci. 2015 Mar;60(3):762-72. doi: 10.1007/s10620-014-3444-4. Review.

9.

A CpG island methylator phenotype of colorectal cancer that is contiguous with conventional adenomas, but not serrated polyps.

Hokazono K, Ueki T, Nagayoshi K, Nishioka Y, Hatae T, Koga Y, Hirahashi M, Oda Y, Tanaka M.

Oncol Lett. 2014 Nov;8(5):1937-1944.

10.

The BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG Island Methylator phenotype.

Fang M, Ou J, Hutchinson L, Green MR.

Mol Cell. 2014 Sep 18;55(6):904-15. doi: 10.1016/j.molcel.2014.08.010.

11.

Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Panczyk M.

World J Gastroenterol. 2014 Aug 7;20(29):9775-827. doi: 10.3748/wjg.v20.i29.9775. Review.

12.

CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.

Shiovitz S, Bertagnolli MM, Renfro LA, Nam E, Foster NR, Dzieciatkowski S, Luo Y, Lao VV, Monnat RJ Jr, Emond MJ, Maizels N, Niedzwiecki D, Goldberg RM, Saltz LB, Venook A, Warren RS, Grady WM; Alliance for Clinical Trials in Oncology..

Gastroenterology. 2014 Sep;147(3):637-45. doi: 10.1053/j.gastro.2014.05.009.

13.

Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer.

Luo HY, Xu RH.

World J Gastroenterol. 2014 Apr 14;20(14):3858-74. doi: 10.3748/wjg.v20.i14.3858. Review.

14.

DNA methylation subgroups and the CpG island methylator phenotype in gastric cancer: a comprehensive profiling approach.

Loh M, Liem N, Vaithilingam A, Lim PL, Sapari NS, Elahi E, Mok ZY, Cheng CL, Yan B, Pang B, Salto-Tellez M, Yong WP, Iacopetta B, Soong R.

BMC Gastroenterol. 2014 Mar 28;14:55. doi: 10.1186/1471-230X-14-55.

16.
17.

Molecular alterations and biomarkers in colorectal cancer.

Grady WM, Pritchard CC.

Toxicol Pathol. 2014 Jan;42(1):124-39. doi: 10.1177/0192623313505155. Review.

18.

S6K2: The Neglected S6 Kinase Family Member.

Pardo OE, Seckl MJ.

Front Oncol. 2013 Jul 24;3:191. doi: 10.3389/fonc.2013.00191.

19.

Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women.

Samadder NJ, Vierkant RA, Tillmans LS, Wang AH, Weisenberger DJ, Laird PW, Lynch CF, Anderson KE, French AJ, Haile RW, Potter JD, Slager SL, Smyrk TC, Thibodeau SN, Cerhan JR, Limburg PJ.

Gastroenterology. 2013 Aug;145(2):348-56.e1-2. doi: 10.1053/j.gastro.2013.05.001.

20.

Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision.

Donada M, Bonin S, Barbazza R, Pettirosso D, Stanta G.

BMC Gastroenterol. 2013 Feb 27;13:36. doi: 10.1186/1471-230X-13-36.

Items per page

Supplemental Content

Support Center